{
  "api_version": "1",
  "request": {
    "url": "https://clinicaltrialsfind.com/api/v1/search.json?intervention=Biological%2FVaccine&page=3",
    "query": {
      "intervention": "Biological/Vaccine",
      "page": 3
    },
    "page_size": 10
  },
  "pagination": {
    "page": 3,
    "page_size": 10,
    "total_count": 1338,
    "total_pages": 134,
    "next_page_url": "https://clinicaltrialsfind.com/api/v1/search.json?intervention=Biological%2FVaccine&page=4&page_size=10",
    "previous_page_url": "https://clinicaltrialsfind.com/api/v1/search.json?intervention=Biological%2FVaccine&page=2&page_size=10"
  },
  "source": "remote",
  "last_synced_at": "2026-10-06T01:03:08.969Z",
  "attribution": "Data derived from public ClinicalTrials.gov records. The official record at https://clinicaltrials.gov/ remains the source of truth for current availability, contacts, and full study details.",
  "notes": [
    "This endpoint exposes only public summary fields — no participant contact emails, phone numbers, or scraped investigator contact details.",
    "For contact information and full protocol detail, follow each trial's `official_url` to the ClinicalTrials.gov record.",
    "This API is a navigational aid. It does not provide medical advice, eligibility determinations, or compensation guarantees."
  ],
  "trials": [
    {
      "nct_id": "NCT00000105",
      "title": "Vaccination With Tetanus and KLH to Assess Immune Responses.",
      "overall_status": "TERMINATED",
      "study_type": "OBSERVATIONAL",
      "phases": [],
      "conditions": [
        "Cancer"
      ],
      "interventions": [
        {
          "name": "Intracel KLH Vaccine",
          "type": "BIOLOGICAL"
        },
        {
          "name": "Biosyn KLH",
          "type": "BIOLOGICAL"
        },
        {
          "name": "Montanide ISA51",
          "type": "DRUG"
        },
        {
          "name": "Tetanus toxoid",
          "type": "BIOLOGICAL"
        }
      ],
      "intervention_types": [
        "BIOLOGICAL",
        "DRUG"
      ],
      "sponsor": "Masonic Cancer Center, University of Minnesota",
      "sponsor_class": "OTHER",
      "healthy_volunteers": true,
      "eligibility": {
        "minimum_age": "18 Years",
        "maximum_age": null,
        "sex": "ALL",
        "summary": "18 Years and older"
      },
      "enrollment_count": 112,
      "start_date": "2002-07",
      "completion_date": "2012-03",
      "has_results": false,
      "last_update_posted_date": "2017-11-29",
      "last_synced_at": "2026-10-06T01:03:08.969Z",
      "location_count": 1,
      "location_summary": "Minneapolis, Minnesota",
      "locations": [
        {
          "city": "Minneapolis",
          "state": "Minnesota"
        }
      ],
      "official_url": "https://clinicaltrials.gov/study/NCT00000105"
    },
    {
      "nct_id": "NCT02986854",
      "title": "Study to Assess the Safety and Immunogenicity of a Single Dose of GlaxoSmithKline's (GSK) Meningococcal MenACWY-CRM Vaccine (Menveo), Administered to Subjects 15 Through 55 Years of Age, Approximately 4-6 Years After Primary ACWY Vaccination",
      "overall_status": "COMPLETED",
      "study_type": "INTERVENTIONAL",
      "phases": [
        "PHASE3"
      ],
      "conditions": [
        "Infections, Meningococcal"
      ],
      "interventions": [
        {
          "name": "Meningococcal (groups A, C, W and Y) oligosaccharide diphtheria CRM-197 conjugate Vaccine (Menveo)",
          "type": "BIOLOGICAL"
        }
      ],
      "intervention_types": [
        "BIOLOGICAL"
      ],
      "sponsor": "GlaxoSmithKline",
      "sponsor_class": "INDUSTRY",
      "healthy_volunteers": true,
      "eligibility": {
        "minimum_age": "15 Years",
        "maximum_age": "55 Years",
        "sex": "ALL",
        "summary": "15 Years to 55 Years"
      },
      "enrollment_count": 704,
      "start_date": "2016-12-08",
      "completion_date": "2017-12-07",
      "has_results": true,
      "last_update_posted_date": "2019-11-25",
      "last_synced_at": "2026-10-06T01:03:08.969Z",
      "location_count": 36,
      "location_summary": "Birmingham, Alabama • Huntsville, Alabama • Chandler, Arizona + 27 more",
      "locations": [
        {
          "city": "Birmingham",
          "state": "Alabama"
        },
        {
          "city": "Huntsville",
          "state": "Alabama"
        },
        {
          "city": "Chandler",
          "state": "Arizona"
        },
        {
          "city": "Anaheim",
          "state": "California"
        },
        {
          "city": "Roseville",
          "state": "California"
        }
      ],
      "official_url": "https://clinicaltrials.gov/study/NCT02986854"
    },
    {
      "nct_id": "NCT00019084",
      "title": "Vaccine Therapy and Biological Therapy in Treating Patients With Advanced Cancer",
      "overall_status": "COMPLETED",
      "study_type": "INTERVENTIONAL",
      "phases": [
        "PHASE2"
      ],
      "conditions": [
        "Breast Cancer",
        "Cervical Cancer",
        "Colorectal Cancer",
        "Lung Cancer",
        "Ovarian Cancer",
        "Pancreatic Cancer"
      ],
      "interventions": [
        {
          "name": "aldesleukin",
          "type": "BIOLOGICAL"
        },
        {
          "name": "mutant p53 peptide pulsed dendritic cell vaccine",
          "type": "BIOLOGICAL"
        },
        {
          "name": "ras peptide cancer vaccine",
          "type": "BIOLOGICAL"
        },
        {
          "name": "sargramostim",
          "type": "BIOLOGICAL"
        },
        {
          "name": "therapeutic autologous lymphocytes",
          "type": "BIOLOGICAL"
        },
        {
          "name": "therapeutic tumor infiltrating lymphocytes",
          "type": "BIOLOGICAL"
        }
      ],
      "intervention_types": [
        "BIOLOGICAL"
      ],
      "sponsor": "National Cancer Institute (NCI)",
      "sponsor_class": "NIH",
      "healthy_volunteers": false,
      "eligibility": {
        "minimum_age": "18 Years",
        "maximum_age": null,
        "sex": "ALL",
        "summary": "18 Years and older"
      },
      "enrollment_count": null,
      "start_date": "1996-02",
      "completion_date": "2003-05",
      "has_results": false,
      "last_update_posted_date": "2013-06-20",
      "last_synced_at": "2026-10-06T01:03:08.969Z",
      "location_count": 1,
      "location_summary": "Bethesda, Maryland",
      "locations": [
        {
          "city": "Bethesda",
          "state": "Maryland"
        }
      ],
      "official_url": "https://clinicaltrials.gov/study/NCT00019084"
    },
    {
      "nct_id": "NCT05031078",
      "title": "Assessing Durable Antibody Response to HPV Vaccination",
      "overall_status": "COMPLETED",
      "study_type": "INTERVENTIONAL",
      "phases": [
        "PHASE4"
      ],
      "conditions": [
        "HPV"
      ],
      "interventions": [
        {
          "name": "Gardasil-9",
          "type": "BIOLOGICAL"
        },
        {
          "name": "Lidocaine injections",
          "type": "DRUG"
        }
      ],
      "intervention_types": [
        "BIOLOGICAL",
        "DRUG"
      ],
      "sponsor": "Emory University",
      "sponsor_class": "OTHER",
      "healthy_volunteers": true,
      "eligibility": {
        "minimum_age": "18 Years",
        "maximum_age": "45 Years",
        "sex": "ALL",
        "summary": "18 Years to 45 Years"
      },
      "enrollment_count": 17,
      "start_date": "2021-12-21",
      "completion_date": "2026-03-26",
      "has_results": true,
      "last_update_posted_date": "2026-08-20",
      "last_synced_at": "2026-10-06T01:03:08.969Z",
      "location_count": 2,
      "location_summary": "Atlanta, Georgia",
      "locations": [
        {
          "city": "Atlanta",
          "state": "Georgia"
        },
        {
          "city": "Atlanta",
          "state": "Georgia"
        }
      ],
      "official_url": "https://clinicaltrials.gov/study/NCT05031078"
    },
    {
      "nct_id": "NCT01505049",
      "title": "Immune Memory After Papillomavirus Vaccination",
      "overall_status": "COMPLETED",
      "study_type": "OBSERVATIONAL",
      "phases": [],
      "conditions": [
        "Healthy Volunteers"
      ],
      "interventions": [
        {
          "name": "quadrivalent HPV vaccine",
          "type": "DRUG"
        }
      ],
      "intervention_types": [
        "DRUG"
      ],
      "sponsor": "Emory University",
      "sponsor_class": "OTHER",
      "healthy_volunteers": true,
      "eligibility": {
        "minimum_age": "18 Years",
        "maximum_age": "30 Years",
        "sex": "FEMALE",
        "summary": "18 Years to 30 Years · Female only"
      },
      "enrollment_count": 203,
      "start_date": "2012-01",
      "completion_date": "2015-01",
      "has_results": false,
      "last_update_posted_date": "2015-07-21",
      "last_synced_at": "2026-10-06T01:03:08.969Z",
      "location_count": 1,
      "location_summary": "Atlanta, Georgia",
      "locations": [
        {
          "city": "Atlanta",
          "state": "Georgia"
        }
      ],
      "official_url": "https://clinicaltrials.gov/study/NCT01505049"
    },
    {
      "nct_id": "NCT00698568",
      "title": "Safety Evaluation of Herpes Simplex Candidate Vaccine (gD2t) With Adjuvant in HSV Seropositive / Seronegative Subjects",
      "overall_status": "COMPLETED",
      "study_type": "INTERVENTIONAL",
      "phases": [
        "PHASE3"
      ],
      "conditions": [
        "Prophylaxis for Herpes Simplex"
      ],
      "interventions": [
        {
          "name": "Herpes simplex candidate vaccine- adjuvanted GSK 208141",
          "type": "BIOLOGICAL"
        },
        {
          "name": "Placebo",
          "type": "BIOLOGICAL"
        }
      ],
      "intervention_types": [
        "BIOLOGICAL"
      ],
      "sponsor": "GlaxoSmithKline",
      "sponsor_class": "INDUSTRY",
      "healthy_volunteers": true,
      "eligibility": {
        "minimum_age": "18 Years",
        "maximum_age": null,
        "sex": "ALL",
        "summary": "18 Years and older"
      },
      "enrollment_count": 7460,
      "start_date": "1996-10",
      "completion_date": "1999-04",
      "has_results": false,
      "last_update_posted_date": "2008-06-17",
      "last_synced_at": "2026-10-06T01:03:08.969Z",
      "location_count": 36,
      "location_summary": "La Jolla, California • Middle Valley, California • San Diego, California + 31 more",
      "locations": [
        {
          "city": "La Jolla",
          "state": "California"
        },
        {
          "city": "Middle Valley",
          "state": "California"
        },
        {
          "city": "San Diego",
          "state": "California"
        },
        {
          "city": "Denver",
          "state": "Colorado"
        },
        {
          "city": "East Lyme",
          "state": "Connecticut"
        }
      ],
      "official_url": "https://clinicaltrials.gov/study/NCT00698568"
    },
    {
      "nct_id": "NCT02193347",
      "title": "IDH1 Peptide Vaccine for Recurrent Grade II Glioma",
      "overall_status": "COMPLETED",
      "study_type": "INTERVENTIONAL",
      "phases": [
        "PHASE1"
      ],
      "conditions": [
        "Brain Cancer",
        "Brain Neoplasm, Primary",
        "Brain Neoplasms, Recurrent",
        "Brain Tumor",
        "Cancer of the Brain"
      ],
      "interventions": [
        {
          "name": "PEPIDH1M vaccine",
          "type": "BIOLOGICAL"
        },
        {
          "name": "Tetanus-Diphtheria Toxoid (Td)",
          "type": "BIOLOGICAL"
        },
        {
          "name": "Temozolomide",
          "type": "DRUG"
        }
      ],
      "intervention_types": [
        "BIOLOGICAL",
        "DRUG"
      ],
      "sponsor": "Katy Peters, MD, PhD",
      "sponsor_class": "OTHER",
      "healthy_volunteers": false,
      "eligibility": {
        "minimum_age": "18 Years",
        "maximum_age": null,
        "sex": "ALL",
        "summary": "18 Years and older"
      },
      "enrollment_count": 24,
      "start_date": "2016-01-28",
      "completion_date": "2020-02-03",
      "has_results": true,
      "last_update_posted_date": "2023-12-01",
      "last_synced_at": "2026-10-06T01:03:08.969Z",
      "location_count": 1,
      "location_summary": "Durham, North Carolina",
      "locations": [
        {
          "city": "Durham",
          "state": "North Carolina"
        }
      ],
      "official_url": "https://clinicaltrials.gov/study/NCT02193347"
    },
    {
      "nct_id": "NCT02633787",
      "title": "Persistence of Bactericidal Antibodies in Adults Who Received a Booster Dose of Menactra® Approximately 4 Years Earlier",
      "overall_status": "COMPLETED",
      "study_type": "INTERVENTIONAL",
      "phases": [
        "PHASE4"
      ],
      "conditions": [
        "Meningitis",
        "Meningococcal Meningitis",
        "Meningococcal Infections"
      ],
      "interventions": [
        {
          "name": "Meningococcal (Groups A, C, Y, and W-135) Polysaccharide Diphtheria Toxoid Conjugate Vaccine",
          "type": "BIOLOGICAL"
        }
      ],
      "intervention_types": [
        "BIOLOGICAL"
      ],
      "sponsor": "Sanofi Pasteur, a Sanofi Company",
      "sponsor_class": "INDUSTRY",
      "healthy_volunteers": true,
      "eligibility": {
        "minimum_age": "18 Years",
        "maximum_age": null,
        "sex": "ALL",
        "summary": "18 Years and older"
      },
      "enrollment_count": 110,
      "start_date": "2015-12",
      "completion_date": "2016-03",
      "has_results": true,
      "last_update_posted_date": "2016-11-07",
      "last_synced_at": "2026-10-06T01:03:08.969Z",
      "location_count": 4,
      "location_summary": "Bardstown, Kentucky • Woburn, Massachusetts • Niles, Michigan + 1 more",
      "locations": [
        {
          "city": "Bardstown",
          "state": "Kentucky"
        },
        {
          "city": "Woburn",
          "state": "Massachusetts"
        },
        {
          "city": "Niles",
          "state": "Michigan"
        },
        {
          "city": "Layton",
          "state": "Utah"
        }
      ],
      "official_url": "https://clinicaltrials.gov/study/NCT02633787"
    },
    {
      "nct_id": "NCT00753272",
      "title": "Trial to Evaluate the Efficacy of GSK Biologicals' Influenza Vaccine GSK2186877A in Adults 65 Year of Age and Older",
      "overall_status": "COMPLETED",
      "study_type": "INTERVENTIONAL",
      "phases": [
        "PHASE3"
      ],
      "conditions": [
        "Influenza"
      ],
      "interventions": [
        {
          "name": "GSK Bio's influenza vaccine GSK2186877A",
          "type": "BIOLOGICAL"
        },
        {
          "name": "Fluarix TM",
          "type": "BIOLOGICAL"
        }
      ],
      "intervention_types": [
        "BIOLOGICAL"
      ],
      "sponsor": "GlaxoSmithKline",
      "sponsor_class": "INDUSTRY",
      "healthy_volunteers": true,
      "eligibility": {
        "minimum_age": "65 Years",
        "maximum_age": null,
        "sex": "ALL",
        "summary": "65 Years and older"
      },
      "enrollment_count": 43695,
      "start_date": "2008-09-15",
      "completion_date": "2011-01-05",
      "has_results": true,
      "last_update_posted_date": "2018-06-08",
      "last_synced_at": "2026-10-06T01:03:08.969Z",
      "location_count": 63,
      "location_summary": "Alabaster, Alabama • Huntsville, Alabama • Mobile, Alabama + 51 more",
      "locations": [
        {
          "city": "Alabaster",
          "state": "Alabama"
        },
        {
          "city": "Huntsville",
          "state": "Alabama"
        },
        {
          "city": "Mobile",
          "state": "Alabama"
        },
        {
          "city": "Chandler",
          "state": "Arizona"
        },
        {
          "city": "Mesa",
          "state": "Arizona"
        }
      ],
      "official_url": "https://clinicaltrials.gov/study/NCT00753272"
    },
    {
      "nct_id": "NCT03711032",
      "title": "Efficacy and Safety of Pembrolizumab (MK-3475) in Combination With Bacillus Calmette-Guerin (BCG) in High-Risk Non-Muscle Invasive Bladder Cancer (HR NMIBC) (MK-3475-676/KEYNOTE-676)",
      "overall_status": "ACTIVE_NOT_RECRUITING",
      "study_type": "INTERVENTIONAL",
      "phases": [
        "PHASE3"
      ],
      "conditions": [
        "High-risk Non-muscle Invasive Bladder Cancer"
      ],
      "interventions": [
        {
          "name": "Pembrolizumab",
          "type": "BIOLOGICAL"
        },
        {
          "name": "BCG",
          "type": "BIOLOGICAL"
        }
      ],
      "intervention_types": [
        "BIOLOGICAL"
      ],
      "sponsor": "Merck Sharp & Dohme LLC",
      "sponsor_class": "INDUSTRY",
      "healthy_volunteers": false,
      "eligibility": {
        "minimum_age": "18 Years",
        "maximum_age": null,
        "sex": "ALL",
        "summary": "18 Years and older"
      },
      "enrollment_count": 1397,
      "start_date": "2018-12-24",
      "completion_date": "2034-11-20",
      "has_results": false,
      "last_update_posted_date": "2026-05-01",
      "last_synced_at": "2026-10-06T01:03:08.969Z",
      "location_count": 44,
      "location_summary": "Anchorage, Alaska • Phoenix, Arizona • Tucson, Arizona + 39 more",
      "locations": [
        {
          "city": "Anchorage",
          "state": "Alaska"
        },
        {
          "city": "Phoenix",
          "state": "Arizona"
        },
        {
          "city": "Tucson",
          "state": "Arizona"
        },
        {
          "city": "Los Angeles",
          "state": "California"
        },
        {
          "city": "Orange",
          "state": "California"
        }
      ],
      "official_url": "https://clinicaltrials.gov/study/NCT03711032"
    }
  ]
}